Pricing Log in Create free account
Friday 6 November 2026 Export XRAY’s income statement to Excel — free account

DENTSPLY SIRONA Inc.

XRAY Healthcare Medical Instruments & Supplies

DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024.

Revenue
−7.52%
EPS
+99.5%
Free cash flow
−18.0%
Total debt
−1.59%

Quarter to September 2026, against a year earlier

9.58 0.51 −5.05%
Market cap
$2.0B
P/E
0.0×
Fwd P/E
24.5×
Dividend yield
1.59%
F-score
6/9
Altman Z
0.50
Beneish M
−3.03
Dividend safety
22/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 1.64
Sold, $m 0.92
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 4 — — 6 — — — — —
Sell 1 — — — — — — — — — — —
Insider Ownership 0.77%

Capital & Financial Ratios $m

Size
Market Cap 2,010.00
Revenue ttm 3,575.00
Net income ttm (122.00)
Free cash flow ttm 272.00
Net debt Q 1,790.00
Valuation
P/E 0.00
Forward P/E 24.50
Price / sales 0.56
Forward P/S Powerpack
Price / FCF 21.14
Price / book 1.48
Financial health
Current ratio Q 1.63 (at or above 1.5: strong)
Debt / equity Q 1.47
Interest coverage Q 1.48
Growth
Revenue growth Q −7.52% (below 0%: shrinking)
Operating income growth Q +116.97% (above 0%: growing)
EPS, this year −6.53% (below 0%: weak)
EPS, next year A −6.15% (below 0%: weak)
Revenue, next year A −3.04% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −1.52% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.1×, against a ten-year median of 2.8×; over the ten years it ranged from 1.0× in 2026 to 5.1× in 2016.
P/S against its own 10 years 2.27%
10-year low 10-year high
P/B against its own 10 years 8.07%
10-year low 10-year high
EV/Sales against its own 10 years 3.63%
10-year low 10-year high
EV/FCF against its own 10 years 84.12%
10-year low 10-year high

Dividends

Yield
1.59%
Annual rate
0.16
Payout ratio
—
Growth, 2017–25
+4.87%/yr
  1. 0.44 ’17
  2. 0.35 ’18 −20
  3. 0.38 ’19 +7
  4. 0.40 ’20 +7
  5. 0.43 ’21 +7
  6. 0.50 ’22 +16
  7. 0.56 ’23 +12
  8. 0.64 ’24 +14
  9. 0.64 ’25 +0
paid change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 334 272 326 195
Receivables 695 556 688 605
Inventory 624 564 642 707
Other — — — —
1,973 1,746 2,023 1,978
2023 2024 2025 Q'26
Payables 305 241 300 238
ST’ Debt — — — —
Other — — — —
1,425 1,589 1,343 1,217

Compound Annual Growth %

10y 5y 3y
Sales 3.24% 1.96% (2.10%)
Cash Flow (7.22%) (18.39%) (23.11%)
Earnings 0.00% 0.00% 0.00%
Book Value (5.42%) (22.95%) (29.43%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.36 Actual 0.52

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.45 0.37 Miss by 0.08
Q4 FY25 0.28 0.27 Miss by 0.01
Q1 FY26 0.28 0.27 Miss by 0.01
Q2 FY26 0.36 0.52 Beat by 0.16
Q3 FY26 0.30 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.05) 0.18 (0.01) — —
’25 0.10 (0.22) (2.14) (0.74) (3.00)
’24 0.09 (0.02) (2.46) (2.16) (4.48)
’23 (0.09) 0.40 (1.25) 0.32 (0.62)
’22 0.30 0.34 (5.01) (0.07) (4.41)
’21 0.53 0.45 0.47 0.47 1.91
’20 (0.63) (0.44) 0.25 0.45 (0.38)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 880 898 836 — —
’25 879 936 904 961 3,680
’24 953 984 951 905 3,793
’23 978 1,028 947 1,012 3,965
’22 969 1,023 947 983 3,922
’21 1,026 1,062 1,040 1,103 4,231
’20 874 491 883 1,091 3,339
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 40 99 32 — —
’25 7 48 79 101 235
’24 25 208 141 87 461
’23 (21) 104 134 160 377
’22 93 173 109 142 517
’21 49 214 172 222 657
’20 (10) 174 221 264 649
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) 60 32 — —
’25 (12) 17 39 60 104
’24 (9) 157 97 36 281
’23 (60) 71 97 120 228
’22 49 132 77 110 368
’21 19 179 136 181 515
’20 (35) 161 199 237 562
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 3,745 3,993 3,986 4,022 3,339 4,231 3,922 3,965 3,793 3,680 3,575 (0.2%) 3,568 3,610 3,700 +0.2%
Gross margin, % 53.42 54.80 51.88 53.80 49.60 55.47 54.23 52.61 51.62 50.00 50.52 (3.4) pt
EBT 441 (1,603) (958) 338 (50) 545 (1,055) (175) (936) (486) (91) n/m
EBT margin, % 11.77 (40.15) (24.03) 8.40 (1.50) 12.88 (26.90) (4.41) (24.68) (13.21) (2.55) (25.0) pt
Net income 431 (1,550) (1,011) 256 (73) 411 (950) (132) (910) (598) (122) n/m
Per share, $
Per share, $ Revenue 17.18 17.41 17.77 18.03 15.23 19.37 18.20 18.70 18.67 18.46 17.95 +0.8%
Earnings 1.97 (6.86) (4.51) 1.18 (0.38) 1.93 (4.41) (0.62) (4.48) (3.00) (0.62) n/m
Cash flow 2.58 2.62 2.23 2.86 2.96 3.01 2.40 1.78 2.27 1.18 1.37 (8.4%)
Capex (0.56) (0.63) (0.80) (0.55) (0.40) (0.65) (0.69) (0.70) (0.89) (0.66) 0.00 +1.9%
Free cash flow 2.03 2.00 1.43 2.31 2.56 2.36 1.71 1.08 1.38 0.52 1.37 (14.0%)
Book value 37.27 28.89 22.88 22.84 22.51 22.88 17.69 15.54 9.56 6.72 6.80 (17.3%)
Shares, m 218 229 224 223 219 218 216 212 203 199 200 (1.0%)
Valuation, ×
Valuation, × P/E 28.88 0.00 0.00 47.96 0.00 29.06 0.00 0.00 0.00 0.00 0.00 10.6
P/S 3.41 3.86 2.09 3.14 3.44 2.88 1.80 1.91 1.02 0.62 0.56 2.4
P/B 1.57 2.32 1.63 2.48 2.33 2.44 1.85 2.29 1.98 1.70 1.48 2.1
EV/Sales 3.71 4.18 2.41 3.39 3.90 3.25 2.17 2.27 1.36 1.08 1.06 2.8
EV/FCF 31.81 36.42 29.91 26.72 23.37 26.98 23.43 40.43 18.73 40.08 39.98 29.8
Cash, $m
Cash, $m Operating cash flow 563 602 500 639 649 657 517 377 461 235 272 (9.3%)
Capex (121) (144) (179) (123) (87) (142) (149) (149) (180) (131) (172) +0.9%
Free cash flow 442 458 321 516 562 515 368 228 281 104 272 (14.9%)
Balance, $m
Balance, $m Working capital 976 1,048 875 1,005 426 591 723 548 157 680 761 (3.9%)
Net debt 1,127 1,291 1,255 1,028 1,540 1,574 1,461 1,462 1,314 1,689 1,790 +4.6%
Shareholders’ equity 8,126 6,628 5,133 5,095 4,935 4,997 3,812 3,294 1,943 1,340 1,354 (18.1%)
Returns, %
Returns, % ROA 5.39 (14.14) (10.61) 2.96 (0.81) 4.42 (11.25) (1.76) (13.87) (10.70) (2.23) (16.1) pt
ROIC 3.07 (12.33) (9.37) 3.60 (0.03) 5.78 (11.11) (1.12) (16.87) (8.71) (1.09) (11.8) pt
ROE 8.22 (21.01) (17.19) 5.01 (1.46) 8.28 (21.57) (3.72) (34.75) (36.43) (8.55) (44.6) pt
People
People Employees 15,700 16,100 16,400 15,200 15,000 15,000 15,000 15,000 14,000 14,000 — (1.3%)
Revenue/emp, $m 0.24 0.25 0.24 0.26 0.22 0.28 0.26 0.26 0.27 0.26 — +1.1%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

DENTSPLY SIRONA Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PLSE Pulse Biosciences, Inc $3.9B — (loss-making) — (loss-making) +359.30% (above 0%: growing) n/m −1,180.54% (below 0%: shrinking) 51.65% (6,149.87%) Compare
STVN Stevanato Group S.p.A. $3.6B 22.4× 30.2× +5.91% (above 0%: growing) +17.53% (above 0%: growing) +4,089.92% (above 0%: growing) 29.12% 18.51% Compare
WRBY Warby Parker Inc. $3.2B 434× 208× +10.40% (above 0%: growing) −20.00% (below 0%: shrinking) −30.28% (below 0%: shrinking) 54.41% 1.45% Compare
ATRC AtriCure, Inc. $3.1B 199× 573× +15.03% (above 0%: growing) n/m −0.73% (below 0%: shrinking) 77.27% 2.82% Compare
XRAY DENTSPLY SIRONA Inc. $2.0B — (loss-making) 24.5× −7.52% (below 0%: shrinking) n/m −17.95% (below 0%: shrinking) 52.99% 4.43%
LMAT LeMaitre Vascular, Inc. $1.9B 29.7× 28.2× +11.34% (above 0%: growing) −14.29% (below 0%: shrinking) −25.78% (below 0%: shrinking) 71.66% 26.03% Compare
KMTS Kestra Medical Technologies, Ltd. $1.7B — (loss-making) — (loss-making) +59.88% (above 0%: growing) n/m −17.75% (below 0%: shrinking) 56.50% (121.59%) Compare
AZTA Azenta, Inc. $1.6B — (loss-making) — (loss-making) +12.04% (above 0%: growing) n/m −134.69% (below 0%: shrinking) 44.89% (2.59%) Compare
STAA STAAR Surgical Company $1.3B — (loss-making) 84.4× −11.95% (below 0%: shrinking) −38.89% (below 0%: shrinking) +1,378.70% (above 0%: growing) 70.90% 6.54% Compare
Median of peers $2.5B 114× 84.4× +11.69% −17.14% −21.76% 55.46% 2.14%

All 53 Medical Instruments & Supplies stocks →

Pay and ownership Proxy statement filed 23 April 2026

Ownership

Directors and executive officers, together 0.46%
The Vanguard Group, Inc., 10.12%
BlackRock, Inc., 9.44%
First Eagle Investment Management, LLC, 7.06%
Fuller & Thaler Asset Management, Inc., 5.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

DENTSPLY SIRONA Inc. (XRAY) Latest News

6 Nov

Impact 4 · · Zacks
Impact 3 · · The Motley Fool transcript

5 Nov

Impact 3 · · StockStory
Impact 3 · · GlobeNewswire

28 Oct

Impact 3 · · Insider Monkey

20 Oct

Impact 3 · · GlobeNewswire

12 Oct

Impact 3 · · Zacks

9 Oct

Impact 3 · · StockStory

8 Oct

Impact 3 · · Simply Wall St.

7 Oct

Impact 3 · · GlobeNewswire

6 Oct

Impact 4 · · GlobeNewswire

23 Sep

Impact 3 · · StockStory

8 Sep

Impact 3 ·

4 Sep

Impact 3 ·
Impact 3 ·

3 Sep

Impact 3 ·

15 Aug

Impact 3 ·

14 Aug

Impact 3 · · The Motley Fool transcript

11 Aug

Impact 3 ·

7 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·
Impact 3 · · Moby

6 Aug

Impact 4 ·
Impact 3 ·
Impact 3 ·

4 Aug

Impact 3 ·

3 Aug

Impact 3 ·

28 Jul

Impact 3 ·

1 Jul

Impact 3 ·

15 Jun

Impact 3 ·

XRAY metrics, ten years each

stockrow.com/XRAY · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com